Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
29 05 2022
Historique:
received: 17 11 2021
accepted: 15 02 2022
pubmed: 25 3 2022
medline: 3 6 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Increased fluconazole and echinocandin resistance in Candida glabrata requires prompt detection in routine settings. A phenotypic test based on the EUCAST E.DEF 7.3.2 protocol was developed for the detection of fluconazole- and anidulafungin-resistant isolates utilizing the colorimetric dye XTT. Thirty-one clinical C. glabrata isolates, 11 anidulafungin resistant and 14 fluconazole resistant, were tested. After optimization studies, 0.5-2.5 × 105 cfu/mL of each isolate in RPMI 1640 + 2% d-glucose medium containing 100 mg/L XTT + 0.78 μΜ menadione and 0.06 mg/L anidulafungin (S breakpoint) or 16 mg/L fluconazole (I breakpoint) in 96-well flat-bottom microtitration plates were incubated at 37°C for 18 h; we also included drug-free wells. XTT absorbance was measured at 450 nm every 15 min. Differences between the drug-free and the drug-treated wells were assessed using Student's t-test at different timepoints. ROC curves were used in order to identify the best timepoint and cut-off. The XTT absorbance differences between fluconazole-containing and drug-free wells were significantly lower for the resistant isolates compared with susceptible increased exposure isolates (0.08 ± 0.05 versus 0.25 ± 0.06, respectively, P = 0.005) at 7.5 h, with a difference of <0.157 corresponding to 100% sensitivity and 94% specificity for detection of resistance. The XTT absorbance differences between anidulafungin-containing and drug-free wells were significantly lower for the resistant isolates compared with susceptible isolates (0.08 ± 0.07 versus 0.200 ± 0.03, respectively, P < 0.001) at 5 h, with a difference of <0.145 corresponding to 91% sensitivity and 100% specificity, irrespective of underlying mutations. A simple, cheap and fast phenotypic test was developed for detection of fluconazole- and anidulafungin-resistant C. glabrata isolates.

Sections du résumé

BACKGROUND
Increased fluconazole and echinocandin resistance in Candida glabrata requires prompt detection in routine settings. A phenotypic test based on the EUCAST E.DEF 7.3.2 protocol was developed for the detection of fluconazole- and anidulafungin-resistant isolates utilizing the colorimetric dye XTT.
METHODS
Thirty-one clinical C. glabrata isolates, 11 anidulafungin resistant and 14 fluconazole resistant, were tested. After optimization studies, 0.5-2.5 × 105 cfu/mL of each isolate in RPMI 1640 + 2% d-glucose medium containing 100 mg/L XTT + 0.78 μΜ menadione and 0.06 mg/L anidulafungin (S breakpoint) or 16 mg/L fluconazole (I breakpoint) in 96-well flat-bottom microtitration plates were incubated at 37°C for 18 h; we also included drug-free wells. XTT absorbance was measured at 450 nm every 15 min. Differences between the drug-free and the drug-treated wells were assessed using Student's t-test at different timepoints. ROC curves were used in order to identify the best timepoint and cut-off.
RESULTS
The XTT absorbance differences between fluconazole-containing and drug-free wells were significantly lower for the resistant isolates compared with susceptible increased exposure isolates (0.08 ± 0.05 versus 0.25 ± 0.06, respectively, P = 0.005) at 7.5 h, with a difference of <0.157 corresponding to 100% sensitivity and 94% specificity for detection of resistance. The XTT absorbance differences between anidulafungin-containing and drug-free wells were significantly lower for the resistant isolates compared with susceptible isolates (0.08 ± 0.07 versus 0.200 ± 0.03, respectively, P < 0.001) at 5 h, with a difference of <0.145 corresponding to 91% sensitivity and 100% specificity, irrespective of underlying mutations.
CONCLUSIONS
A simple, cheap and fast phenotypic test was developed for detection of fluconazole- and anidulafungin-resistant C. glabrata isolates.

Identifiants

pubmed: 35323941
pii: 6551886
doi: 10.1093/jac/dkac075
pmc: PMC9840476
doi:

Substances chimiques

Antifungal Agents 0
Echinocandins 0
Fluconazole 8VZV102JFY
Anidulafungin 9HLM53094I

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1655-1661

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Clin Microbiol Rev. 2001 Oct;14(4):836-71, table of contents
pubmed: 11585788
J Clin Microbiol. 1998 May;36(5):1450-2
pubmed: 9574729
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 30021820
Mycoses. 2006 Jul;49(4):261-73
pubmed: 16784439
Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S612-7
pubmed: 26567278
Clin Microbiol Infect. 2019 Jul;25(7):792-798
pubmed: 30965100
J Antimicrob Chemother. 2007 Feb;59(2):230-7
pubmed: 17185296
Mycoses. 2015 Jun;58 Suppl 2:2-13
pubmed: 26033251
J Med Microbiol. 2001 Apr;50(4):375-382
pubmed: 11289523
J Antimicrob Chemother. 2005 Jan;55(1):106-9
pubmed: 15546969
J Clin Microbiol. 2013 Sep;51(9):2964-9
pubmed: 23824764
FEMS Microbiol Rev. 2019 Sep 1;43(5):517-547
pubmed: 31158289
Nat Protoc. 2008;3(9):1494-500
pubmed: 18772877
J Clin Microbiol. 2001 Dec;39(12):4256-63
pubmed: 11724829
Antimicrob Agents Chemother. 1992 Aug;36(8):1619-25
pubmed: 1416843
Future Microbiol. 2014;9(8):947-67
pubmed: 25302953
Nat Rev Dis Primers. 2018 May 11;4:18026
pubmed: 29749387
J Fungi (Basel). 2018 Sep 01;4(3):
pubmed: 30200517
J Infect Dis. 2017 Aug 15;216(suppl_3):S445-S451
pubmed: 28911043
Clin Microbiol Infect. 2012 Jul;18(7):E246-7
pubmed: 22563750
Curr Opin Infect Dis. 2017 Dec;30(6):528-538
pubmed: 29095200
Int J Antimicrob Agents. 2017 Nov;50(5):599-606
pubmed: 28669835
Clin Infect Dis. 2008 Jan 1;46(1):120-8
pubmed: 18171227
J Clin Microbiol. 2006 Feb;44(2):553-60
pubmed: 16455912
Diagn Microbiol Infect Dis. 1996 Jul;25(3):117-21
pubmed: 8902406
PLoS One. 2012;7(3):e33818
pubmed: 22439000
Curr Opin Infect Dis. 2009 Dec;22(6):568-73
pubmed: 19741524
J Clin Microbiol. 2001 Jul;39(7):2458-62
pubmed: 11427554
Mycoses. 2012 May;55(3):e90-6
pubmed: 22035475

Auteurs

Panagiota-Christina Georgiou (PC)

Clinical Microbiology Laboratory, Attikon University Hospital, Athens, Greece.

Maiken Cavling Arendrup (MC)

Unit of Mycology, Statens Serum Institute, Copenhagen, Denmark.
Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Joseph Meletiadis (J)

Clinical Microbiology Laboratory, Attikon University Hospital, Athens, Greece.
Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH